Animal genetics group Genus (LSE:GNS) has delivered sharply higher earnings, a firmer balance sheet and a new £60 million buyback, yet its share price remains well down on the year as investors weigh the pace of its gene-edited pig programme.

Genus, the FTSE 250 animal genetics company behind the PIC pig and ABS cattle breeding businesses, finds itself in an unusual position this autumn. Its full-year results, published on 10 September, showed profits rising sharply and debt falling sharply. Yet the shares fell by more than 6% on the day, and in early October they were trading at around 2,159p, roughly 17% lower since the start of the year and well below a 52-week high above 3,200p.

The disconnect highlights how much of the investment case now rests on expectations for future growth rather than the latest numbers, particularly regarding the commercialisation of the company's PRRS-resistant pig, or PRP, a gene-edited animal designed to resist one of the most costly diseases in global pork production.

Solid numbers for the year to June

For the twelve months to 30 June 2026, revenue slipped 2% to £658.1 million, mainly reflecting the deconsolidation of PIC's business in China. Underneath that, profitability improved markedly. Adjusted profit before tax rose 35% to £100.2 million, although the company said that on a normalised basis the figure was £90.3 million. Adjusted earnings per share also increased 35% to 110.3p, and the adjusted operating margin widened by 3.8 percentage points to 17.7%.

PIC, the larger division, increased adjusted operating profit by 17% to £130.8 million, with royalty revenue up 5% and particularly healthy growth in Asia and among joint ventures. The ABS bovine business, which has been through a restructuring and value acceleration programme, also lifted operating profit by 17% to £22.9 million as its margin improved to 7.5%.

Cash generation was a highlight. Free cash flow climbed to £62.0 million from £40.9 million, and net debt fell to £71.8 million from £228.2 million a year earlier, cutting leverage to 0.4 times. On the back of that balance sheet strength, the board raised the full-year dividend by 10% to 35.2p and launched a £60 million share buyback expected to complete during the current financial year.

Why the market remains cautious

The muted share price response appears to stem largely from guidance. Management said it expects adjusted profit before tax for the year to June 2027 to be in line with market consensus and moderately ahead of the normalised £90.3 million, with both divisions forecast to deliver moderate profit growth and earnings weighted to the second half. For a stock that had previously been valued partly on the prospect of rapid PRP-driven growth, that measured outlook appears to have prompted some investors to reassess near-term expectations.

The PRP programme itself continues to advance. The pig has now been cleared in eight jurisdictions, including the United States, where the Food and Drug Administration approved the gene edit in April 2025, as well as Brazil, Canada, Argentina and, most recently, Peru in June 2026. However, approvals in Mexico, Japan and China, which are seen as important for opening up export routes for US pork producers, remain in process. Large-scale commercial adoption in the US is likely to depend on those key trading partners being in place, which has kept the timing of meaningful revenue uncertain.

Looking ahead

For now, Genus (LSE:GNS) is being supported by improving margins in its core breeding operations, healthy cash flow and capital returns. Investors will be watching for further regulatory progress on PRP, the impact of the buyback on the share count, and any update on trading at the annual general meeting later in the autumn. Producer profitability in pork and dairy markets will also matter.